MRD Testing Market

Industry Overview

The global Minimal Residual Disease (MRD) Testing market was estimated at USD 1.4 billion in 2023 and is poised to grow up to USD 3.4 billion by 2030, registering a CAGR of 14.7% during the forecast period ranging between 2025 and 2030.

Global MRD Testing Market: Industry Overview

Minimal residual disease (MRD) testing refers to a specific type of medical test. It involves identifying and monitoring small amounts of cancer cells that may be left behind in a patient's body after undergoing a cancer treatment and may eventually relapse. This particular test can identify cancer cells of leukemia, lymphoma, multiple myeloma, and even a few solid tumors. Various sensitive methods and technologies are used for MRD testing, such as cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), and the results help doctors to make more informed decisions and design a treatment plan accordingly.

The growth of the global MRD testing market is primarily driven by the growing prevalence of hematologic malignancies. It is also attributed to the growing emphasis on personalized medicineand developments in diagnosticsto improve accuracy. Furthermore, development and use of innovative therapies, such as CAR T-cell therapy, needs precise assessment of treatment to determine its success. This is facilitated by MRD testing, which promotes its demand and fuels market growth. Furthermore, the rising awareness among patients regarding the importance of early detection is encouraging healthcare providers to adopt sophisticated MRD testing tools, pushing market expansion further.

Global MRD Testing Market Report Coverage

Despite the positive growth prospects, the market faces significant challenges that impede its growth, such as the high cost and limited accessibility of MRD tests in low-income regions. However, growth opportunities lie in the technological innovations that are lowering the cost of these tests and improving sensitivity and results. Furthermore, with the improvement in healthcare infrastructurein emerging markets and government funding along with collaborative efforts, the market is expected to benefit significantly.

Global MRD Testing Industry Dynamics

Global MRD Testing Market Trends / Growth Drivers:

Growing emphasis on precision medicine

Several significant trends are shaping the global Minimal Residual Disease (MRD) Testing market, the major one being a growing emphasis on precision medicine. This notable shift calls for tailored therapies which doctors can design only after accurate MRD testing to know the unique disease characteristics of each patient. Furthermore, technological advancements, such as the integration of artificial intelligence (AI) and machine learning in diagnostic testing, are also emerging. In addition, progress in sequencing technologies, increased integration of MRD testing in clinical trials, developments in the area of bioinformatics, increased and favorable regulatory support, and higher focus on cost-effective solutions are other significant trends worth noting.

The growing demand for MRD testing due to the improvements in molecular diagnostic technologies, such as digital PCR and artificial intelligence-based platforms is one significant factor driving the growth of theglobal Minimal Residual Disease (MRD) Testing market. These technologies offer greater accuracy and sensitivity while detecting minimal residual disease thereby facilitating more precise monitoring of disease progression. Moreover, the growing adoption of liquid biopsy techniques due to its non-invasive nature compared to traditional tissue biopsies is also increasing the demand for MRD testing and pushing the market forward. Apart from these, the rise in healthcare spending in developing countries and higher integration of MRD testing in clinical trials for evaluating the effectiveness of novel cancer therapies such as immunotherapies that provide better outcomes are also fueling the market growth.

Global MRD Testing Market Challenges:

One of the major challenges faced by the market is the high cost of advanced diagnostic tools. This limits accessibility and adoption of these tests particularly in lower and middle-income groups. In addition, the complexities involved in MRD testing requiring highly trained professionals and equipment to conduct them also limits the market expansion. Furthermore, higher operational costs make it difficult for smaller laboratories to offer such service. Additionally, inconsistencies in healthcare reimbursement policies impact affordability and absence of standardized testing protocols hinders the widespread adoption of MRD testing and the market growth.

Global MRD Testing Market Opportunities:

Nevertheless, the global Minimal Residual Disease (MRD) Testing market has significant growth prospects in the rising emphasis on precision medicine in oncology and higher investments by the governments in developing countries like India and China in healthcare infrastructure and cancer research. Also, strategic collaborations between pharmaceutical firms and major diagnostic companies foster innovation, development of cost-effective solutions, and demand for MRD testing,creating new growth avenues for market growth. Inclusion of advanced technologies like AI and machine learning in data analysis ensures higher efficiency and accuracy of MRD tests and makes them more accessible to a broader patient population, creating novel growth opportunities for the market.

Recent Development By Key Players

GRAIL, LLC collaborated with Sarah Cannon Cancer Institute which is a part of HCA Healthcare when it can be cured, to advance comprehensive cancer care through early detection. Multi-cancer early detection (MCED) test shall be available to patients who meet screening criteria at select HCA Healthcare physician practices.

Guardant Health, Inc.(a leading precision oncology company) and Hikma Pharmaceuticals PLC (a multinational pharmaceutical company) partnered to promote Guardant Health's portfolio of liquid and tissue biopsy tests for tumor mutation profiling for all solid cancers, cancer screening and recurrence monitoring across the Middle East and North Africa (MENA).

Global MRD Testing Market Segmentation

VynZ Research provides an analysis of the key trends in each segment of the global MRD Testing Market report, along with forecasts at the global, regional and country levels from 2025-2030. Our report has categorized the market based on test type, application, therapy and end-user.

Insight by Test Type

The PCR-based test section currently dominates the market and is expected to do so in the forecast period

The global Minimal Residual Disease (MRD) Testing marketis segmented by different test types into polymerase chain reaction (PCR), Next-Generation Sequencing (NGS), flow cytometry, and others segments. Among all these segments, the PCR-based test section currently dominates the market and is expected to do so in the forecast period due to the widespread use in detectingminimal residual disease in blood cancers. However, NGS is likely to witness the fastest growth rate during this period due to its high sensitivity, increased adoption in clinical environments, and ability to detect miniscule quantities of residual cancer cells.The global Minimal Residual Disease (MRD) Testing marketis segmented by different test typesinto polymerase chain reaction (PCR), Next-Generation Sequencing (NGS), flow cytometry, and others segments. Among all these segments, the PCR-based test section currently dominates the market and is expected to do so in the forecast period due to the widespread use in detectingminimal residual disease in blood cancers. However, NGS is likely to witness the fastest growth rate during this period due to its high sensitivity, increased adoption in clinical environments, and ability to detect miniscule quantities of residual cancer cells.

Insight by Application

The leukemia section holds the largest share of the market and dominates the market

The varied application of these tests divides the global Minimal Residual Disease (MRD) Testing market into different sections, namely leukemia, lymphoma, and myeloma. Among these categories, the leukemia section holds the largest share of the market and dominates it due to the high prevalence of hematologic malignancies and its wider adoption. It is also attributed to the growing demand for monitoring tools that are able to detect relapse at earlier stages. The lymphoma segment, on the other hand, is also expected to grow at quite a significant rate during the projected period due to its ability to detect disease progression in specific cases, such as non-Hodgkin lymphoma.

Insight by Therapy

The chemotherapy section remains the most common form of treatment for hematologic malignancies and dominates the market

The different sections of the global Minimal Residual Disease (MRD) Testing market based on different therapies include chemotherapy, immunotherapy, targeted therapy, and stem cell therapy. Out of these four major sections, the chemotherapy section remains the most common form of treatment for hematologic malignancies and dominates the market due to its higher adoption and use for its higher effectiveness in detecting any risk of relapse early. On the flip side, the immunotherapy and targeted therapy sections are also gaining importance steadily due to the progress of innovative treatments such as CAR T-cell therapy.

Insight by End User

The diagnostic laboratories section holds the largest market share.

Different end users in the global Minimal Residual Disease (MRD) Testing marketalso segregates it into different categories, such as hospitals, diagnostic laboratories, academic and research institutions, and others. Out of these sections, the diagnostic laboratories section holds the largest market share. This is attributed to its the advanced technologies used for such tests and availability of trained personnel to perform them. The hospital section is, however, projected to experience a significant growth rate during the forecast period as well due to the growing adoption of in-house diagnostic capabilities to improve its in-house cancer care, diagnostics, therapies, and monitoring, all under one roof.

Global MRD Testing Market: Geographic Overview

North America currently dominates the global Minimal Residual Disease (MRD) Testing market, mainly due to its developed healthcare infrastructure, existence of large number of players in the region especially in US, higher government funding for cancer research, the growing focus of the region on precision medicine, and greater adoption of advanced diagnostic technologies.

The Asia-Pacific region, in contrast, is likely to grow at a highest rate due to higher healthcare investments, improving diagnostic competencies, and growing awareness of early cancer detection in the population of developing countries like India, China, and Japan.

Global MRD Testing Market Competitive Insight

The report provides a comprehensive analysis of the competitive landscape in the market. Some of the key players in the market include:

Source: VynZ Research

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                1.2.1.    By Test Type
                1.2.2.    By Application  
                1.2.3.    By Therapy
                1.2.4.    By End User 
                1.2.5.    By Region
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                1.5.1.  Data Sources
                        1.5.1.1. Primary Research
                        1.5.1.2. Secondary Research
                1.5.2.  Methodology
                        1.5.2.1. Data Exploration
                        1.5.2.2. Forecast Parameters
                        1.5.2.3. Data Validation
                        1.5.2.4. Assumptions
                1.5.3.    Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

        3.1.    Industry Dynamics
                3.1.1.    Market Growth Drivers
                3.1.2.    Market Restraints
                3.1.3.    Key Market Trends
                3.1.4.    Major Opportunities
        3.2.    Industry Ecosystem
                3.2.1.    Porter’s Five Forces Analysis
                3.2.2.    Recent Development Analysis
                3.2.3.    Value Chain Analysis
        3.3.    Competitive Insight
                3.3.1.    Competitive Position of Industry Players
                3.3.2.    Market Attractive Analysis
                3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

        4.1.    Global Market Overview
        4.2.    Global Market Estimate and Forecast to 2030

5.    Market Segmentation Estimate and Forecast

        5.1.    By Test Type
                5.1.1.  Polymerase Chain Reaction (PCR) 
                        5.1.1.1. Market Definition
                        5.1.1.2. Market Estimation and Forecast to 2030 
                5.1.2.  Next-Generation Sequencing (NGS)
                        5.1.2.1. Market Definition
                        5.1.2.2. Market Estimation and Forecast to 2030
                 5.1.3.    Flow Cytometry
                        5.1.3.1. Market Definition
                        5.1.3.2. Market Estimation and Forecast to 2030
                 5.1.4.    Others
                        5.1.4.1. Market Definition
                        5.1.4.2. Market Estimation and Forecast to 2030
        5.2.    By Application  
                5.2.1.  Leukemia
                        5.2.1.1. Market Definition
                        5.2.1.2. Market Estimation and Forecast to 2030
                5.2.2.  Lymphoma
                        5.2.2.1. Market Definition
                        5.2.2.2. Market Estimation and Forecast to 2030
                5.2.3.  Myeloma 
                        5.2.3.1. Market Definition
                        5.2.3.2. Market Estimation and Forecast to 2030
        5.3    By Therapy 
                5.3.1.  Chemotherapy
                        5.3.1.1. Market Definition
                        5.3.1.2. Market Estimation and Forecast to 2030    
                5.3.2.  Immunotherapy
                        5.3.2.1. Market Definition
                        5.3.2.2. Market Estimation and Forecast to 2030    
                5.3.3.    Targeted Therapy
                        5.3.3.1. Market Definition
                        5.3.3.2. Market Estimation and Forecast to 2030    
                5.3.4.    Stem Cell Therapy
                        5.3.4.1. Market Definition
                        5.3.4.2. Market Estimation and Forecast to 2030    
    5.4.    By  End User
                5.4.1.    Hospitals
                        5.4.1.1. Market Definition
                        5.4.1.2. Market Estimation and Forecast to 2030
                5.4.2.    Diagnostic Laboratories
                        5.4.2.1. Market Definition
                        5.4.2.2. Market Estimation and Forecast to 2030
                5.4.3.    Academic and Research Institutions 
                        5.4.3.1. Market Definition
                        5.4.3.2. Market Estimation and Forecast to 2030
                 5.4.4.    Others
                        5.4.4.1. Market Definition
                        5.4.4.2. Market Estimation and Forecast to 2030
                  
6.    North America Market Estimate and Forecast

    6.1.    By Test Type  
    6.2.    By Application  
    6.3.    By Therapy 
    6.4.    By End User
                6.5.1.    U.S. Market Estimate and Forecast
                6.5.2.    Canada Market Estimate and Forecast
                6.5.3.    Mexico Market Estimate and Forecast

7.    Europe Market Estimate and Forecast

    7.1.    By Test Type  
    7.2.    By Application  
    7.3.    By Therapy 
    7.4.    By End User
                7.5.1.    Germany Market Estimate and Forecast
                7.5.2.    France Market Estimate and Forecast
                7.5.3.    U.K. Market Estimate and Forecast
                7.5.4.    Italy Market Estimate and Forecast
                7.5.5.    Spain Market Estimate and Forecast
                7.5.6.    Rest of Europe Market Estimate and Forecast

8.    Asia-Pacific Market Estimate and Forecast

    8.1.    By Test Type  
    8.2.    By Application  
    8.3.    By Therapy 
    8.4.    By End User
    8.5.    By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific
                8.5.1.    China Market Estimate and Forecast
                8.5.2.    Japan Market Estimate and Forecast
                8.5.3.    India Market Estimate and Forecast
                8.5.4.    South Korea Market Estimate and Forecast
                8.5.5.    Singapore Market Estimate and Forecast
                8.5.6.    Rest of Asia-Pacific Market Estimate and Forecast

9.    Rest of the World (RoW) Market Estimate and Forecast

    9.1.    By Test Type  
    9.2.    By Application  
    9.3.    By Therapy 
    9.4.    By End User
    9.5.    By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries
                9.5.1.    Brazil Market Estimate and Forecast
                9.5.2.    Saudi Arabia Market Estimate and Forecast
                9.5.3.    South Africa Market Estimate and Forecast
                9.5.4.    Other Countries Market Estimate and Forecast

10.    Company Profiles

        10.1.   Exact Sciences Corporation
                10.1.1.    Snapshot
                10.1.2.    Overview
                10.1.3.    Offerings
                10.1.4.    Financial Insight
                10.1.5.    Recent Developments
        10.2.   GRAIL LLC
                10.2.1.    Snapshot
                10.2.2.    Overview
                10.2.3.    Offerings
                10.2.4.    Financial Insight
                10.2.5.    Recent Developments
        10.3.   Guardant Health
                10.3.1.    Snapshot
                10.3.2.    Overview
                10.3.3.    Offerings
                10.3.4.    Financial Insight
                10.3.5.    Recent Developments
        10.4.   max health
                10.4.1.    Snapshot
                10.4.2.    Overview
                10.4.3.    Offerings
                10.4.4.    Financial Insight
                10.4.5.    Recent Developments
        10.5.   Bio-Techne.QIAGEN
                10.5.1.    Snapshot
                10.5.2.    Overview
                10.5.3.    Offerings
                10.5.4.    Financial Insight
                10.5.5.    Recent Developments
        10.6.   Veracyte Inc.
                10.6.1.    Snapshot
                10.6.2.    Overview
                10.6.3.    Offerings
                10.6.4.    Financial Insight
                10.6.5.    Recent Developments
        10.7.   F. Hoffmann-La Roche Ltd
                10.7.1.    Snapshot
                10.7.2.    Overview
                10.7.3.    Offerings
                10.7.4.    Financial Insight
                10.7.5.    Recent Developments
        10.8.   FOUNDATION MEDICINE
                10.8.1.    Snapshot
                10.8.2.    Overview
                10.8.3.    Offerings
                10.8.4.    Financial Insight
                10.8.5.    Recent Developments
        10.9.   INC.
                10.9.1.    Snapshot
                10.9.2.    Overview
                10.9.3.    Offerings
                10.9.4.    Financial Insight
                10.9.5.    Recent Developments
    10.10.    Natera Inc.
                10.10.1.    Snapshot
                10.10.2.    Overview
                10.10.3.    Offerings
                10.10.4.    Financial Insight
                10.10.5.    Recent Developments
                
11.    Appendix

        11.1.    Exchange Rates
        11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.

List of Tables

Table 1 Test Types
Table 2 Study Periods
Table 3 Data Reporting Unit
Table 4 Global MRD Testing Market  Size, by Test Type, 2018-2023 (USD Billion)
Table 5 Global MRD Testing Market  Size, by Test Type, 2025-2030 (USD Billion)
Table 6 Global MRD Testing Market  Size, by Application, 2018-2023 (USD Billion)
Table 7 Global MRD Testing Market  Size, by Application, 2025-2030 (USD Billion)
Table 8 Global MRD Testing Market  Size, by Therapy, 2018-2023 (USD Billion)
Table 9 Global MRD Testing Market  Size, by Therapy, 2025-2030 (USD Billion)
Table 10 Global MRD Testing Market  Size, by End User, 2018-2023 (USD Billion)
Table 11 Global MRD Testing Market  Size, by End User, 2025-2030 (USD Billion)
Table 12 Global MRD Testing Market  Size, by Region, 2018-2023 (USD Billion)
Table 13 Global MRD Testing Market  Size, by Region, 2025-2030 (USD Billion)
Table 14 North America MRD Testing Market  Size, by Test Type, 2018-2023 (USD Billion)
Table 15 North America MRD Testing Market  Size, by Test Type, 2025-2030 (USD Billion)
Table 16 North America MRD Testing Market  Size, by Application, 2018-2023 (USD Billion)
Table 17 North America MRD Testing Market  Size, by Application, 2025-2030 (USD Billion)
Table 18 North America MRD Testing Market  Size, by Therapy, 2018-2023 (USD Billion)
Table 19 North America MRD Testing Market  Size, by Therapy, 2025-2030 (USD Billion)
Table 20 North America MRD Testing Market  Size, by End User, 2018-2023 (USD Billion)
Table 21 North America MRD Testing Market  Size, by End User, 2025-2030 (USD Billion)
Table 22 North America MRD Testing Market  Size, by Country, 2018-2023 (USD Billion)
Table 23 North America MRD Testing Market  Size, by Country, 2025-2030 (USD Billion)
Table 24 Europe MRD Testing Market  Size, by Test Type, 2018-2023 (USD Billion)
Table 25 Europe MRD Testing Market  Size, by Test Type, 2025-2030 (USD Billion)
Table 26 Europe MRD Testing Market  Size, by Application, 2018-2023 (USD Billion)
Table 27 Europe MRD Testing Market  Size, by Application, 2025-2030 (USD Billion)
Table 28 Europe MRD Testing Market  Size, by Therapy, 2018-2023 (USD Billion)
Table 29 Europe MRD Testing Market  Size, by Therapy, 2025-2030 (USD Billion)
Table 30 Europe MRD Testing Market  Size, by End User, 2018-2023 (USD Billion)
Table 31 Europe MRD Testing Market  Size, by End User, 2025-2030 (USD Billion)
Table 32 Europe MRD Testing Market  Size, by Country, 2018-2023 (USD Billion)
Table 33 Europe MRD Testing Market  Size, by Country, 2025-2030 (USD Billion)
Table 34 Asia-Pacific MRD Testing Market  Size, by Test Type, 2018-2023 (USD Billion)
Table 35 Asia-Pacific MRD Testing Market  Size, by Test Type, 2025-2030 (USD Billion)
Table 36 Asia-Pacific MRD Testing Market  Size, by Application, 2018-2023 (USD Billion)
Table 37 Asia-Pacific MRD Testing Market  Size, by Application, 2025-2030 (USD Billion)
Table 38 Asia-Pacific MRD Testing Market  Size, by Therapy, 2018-2023 (USD Billion)
Table 39 Asia-Pacific MRD Testing Market  Size, by Therapy, 2025-2030 (USD Billion)
Table 40 Europe MRD Testing Market  Size, by End User, 2018-2023 (USD Billion)
Table 41 Europe MRD Testing Market  Size, by End User, 2025-2030 (USD Billion)
Table 42 Asia-Pacific MRD Testing Market  Size, by Country, 2018-2023 (USD Billion)
Table 43 Asia-Pacific MRD Testing Market  Size, by Country, 2025-2030 (USD Billion)
Table 44 RoW MRD Testing Market  Size, by Test Type, 2018-2023 (USD Billion)
Table 45 RoW MRD Testing Market  Size, by Test Type, 2025-2030 (USD Billion)
Table 46 RoW MRD Testing Market  Size, by Application, 2018-2023 (USD Billion)
Table 47 RoW MRD Testing Market  Size, by Application, 2025-2030 (USD Billion)
Table 48 RoW MRD Testing Market  Size, by Therapy, 2018-2023 (USD Billion)
Table 49 RoW MRD Testing Market  Size, by Therapy, 2025-2030 (USD Billion)
Table 50 RoW MRD Testing Market  Size, by End User, 2018-2023 (USD Billion)
Table 51 RoW MRD Testing Market  Size, by End User, 2025-2030 (USD Billion)
Table 52 RoW MRD Testing Market  Size, by Country, 2018-2023 (USD Billion)
Table 53 RoW MRD Testing Market  Size, by Country, 2025-2030 (USD Billion)
Table 54 Snapshot – Exact Sciences Corporation
Table 55 Snapshot – GRAIL LLC
Table 56 Snapshot – Guardant Health
Table 57 Snapshot – max health
Table 58 Snapshot – Bio-Techne.QIAGEN
Table 59 Snapshot – Veracyte Inc.
Table 60 Snapshot – F.Hoffmann-La Roche Ltd
Table 61 Snapshot – FOUNDATION MEDICINE
Table 62 Snapshot – INC.
Table 63 Snapshot – Natera Inc.

List of Figures

Figure 1 Market Coverage
Figure 2 Research Phases
Figure 3 Secondary  Test Types for Different Parameters
Figure 4 Methodology
Figure 5 Data Mining & Exploration
Figure 6 Data Triangulation
Figure 7 Assumptions for Market Estimation and Forecast
Figure 8 Market Synopsis
Figure 9  Global MRD Testing Market - Growth Drivers and Restraints
Figure 10 Competitive Benchmark
Figure 11 Global MRD Testing Market Highlight
Figure 12 Global MRD Testing Market Size, by  Test Type, 2018 – 2030 (USD Billion)
Figure 13 Global MRD Testing Market Size, by Application 2018 – 2030 (USD Billion)
Figure 14 Global MRD Testing Market Size, by End User 2018 – 2030 (USD Billion)
Figure 15 Global MRD Testing Market Size, by Therapy   2018 – 2030 (USD Billion)
Figure 16 Global MRD Testing Market Size, by Region, 2018 – 2030 (USD Billion)
Figure 17 North America MRD Testing Market Highlight
Figure 18 North America MRD Testing Market Size, by  Test Type, 2018 – 2030 (USD Billion)
Figure 19 North America MRD Testing Market Size, by Application 2018–2030 (USD Billion)
Figure 20 North America MRD Testing Market Size, by End User 2018–2030 (USD Billion)
Figure 21 Global MRD Testing Market Size, by Therapy   2018 – 2030 (USD Billion)
Figure 22 North America MRD Testing Market Size, by Country, 2018 – 2030 (USD Billion)
Figure 23 Europe MRD Testing Market Highlight
Figure 24 Europe MRD Testing Market Size, by  Test Type, 2018 – 2030 (USD Billion)
Figure 25 Europe MRD Testing Market Size, by Application 2018 – 2030 (USD Billion)
Figure 26 Europe MRD Testing Market Size, by Application  2018 – 2030 (USD Billion)
Figure 27 Global MRD Testing Market Size, by Therapy   2018 – 2030 (USD Billion)
Figure 28 Europe MRD Testing Market Size, by Country, 2018 – 2030 (USD Billion)
Figure 29 Asia-Pacific MRD Testing Market Highlight
Figure 30 Asia-Pacific MRD Testing Market Size, by  Test Type, 2018 – 2030 (USD Billion)
Figure 31 Asia-Pacific MRD Testing Market Size, by Application 2018 – 2030 (USD Billion)
Figure 32 Asia-Pacific MRD Testing Market Size, by End User 2018 – 2030 (USD Billion)
Figure 33 Global MRD Testing Market Size, by Therapy   2018 – 2030 (USD Billion)
Figure 34 Asia-Pacific MRD Testing Market Size, by Country, 2018 – 2030 (USD Billion)
Figure 35 RoW MRD Testing Market Highlight
Figure 36 RoW MRD Testing Market Size, by  Test Type, 2018 – 2030 (USD Billion)
Figure 37 RoW MRD Testing Market Size, by Application 2018 – 2030 (USD Billion)
Figure 38 RoW MRD Testing Market Size, by End User 2018 – 2030 (USD Billion)
Figure 39 Global MRD Testing Market Size, by Therapy   2018 – 2030 (USD Billion)
Figure 40 RoW MRD Testing Market Size, by Country, 2018 – 2030 (USD Billion)